A Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects With a History of Stress Urinary Incontinence

Sponsor
Pneumoflex Systems, LLC (Industry)
Overall Status
Completed
CT.gov ID
NCT00801203
Collaborator
Ockham Development Group (Other)
180
10
2
7
18
2.6

Study Details

Study Description

Brief Summary

This study is to evaluate the effectiveness of identifying stress urinary incontinence (SUI) in female subjects using the Induced Reflex Cough Test (IRCT) administered with urodynamic testing by evaluation of sensitivity and specificity.

Condition or Disease Intervention/Treatment Phase
Phase 2/Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
180 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Official Title:
A Phase II/III Controlled Study to Evaluate the Effectiveness of the Induced Reflex Cough Test Plus Urodynamics to Identify Stress Urinary Incontinence in Female Subjects With a History of Stress Urinary Incontinence
Study Start Date :
Dec 1, 2008
Actual Primary Completion Date :
Jul 1, 2009
Actual Study Completion Date :
Jul 1, 2009

Arms and Interventions

Arm Intervention/Treatment
Experimental: 1

Induced Reflex Cough Test (IRCT) followed by Voluntary Cough Test (VCT)

Drug: IRCT
Up to two administrations of the IRCT during a single cough testing session

Experimental: 2

Voluntary Cough Test (VCT) followed by Induced Reflex Cough Test (IRCT)

Drug: IRCT
Up to two administrations of the IRCT during a single cough testing session

Outcome Measures

Primary Outcome Measures

  1. Sensitivity to identify SUI in women with a history of SUI and specificity to not identify SUI in healthy women without a history of SUI [Study Day 1]

Secondary Outcome Measures

  1. Positive predictive value (PPV) and negative predictive value (NPV) of the IRCT administered with urodynamic testing [Study Day 1]

  2. Urodynamic parameters after IRCT and VCT in normal healthy women and women with a history of SUI [Study Day 1]

Eligibility Criteria

Criteria

Ages Eligible for Study:
25 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Women >25 years of age

  • History of SUI (except for healthy controls)

  • Healthy or stable medical problems (no change in 3 months)

  • Willingness and ability to undergo all the study procedures

  • Stable medications are allowed except for prescription and over-the-counter medications with anticholinergic or α-agonistic properties that can affect the bladder or urethra; these must be discontinued at least 2 weeks prior to evaluation

  • Able to understand and sign the informed consent document.

Exclusion Criteria:
  • Body mass index (BMI) >40

  • History of severe arthritis of the hips, knees, or feet that could limit mobility during the study

  • Prior treatment of any kind (surgical or pharmacologic) for incontinence at least 30 days before the cough testing session including treatment with slings, botox, interstim and all bulking agents

  • Prior pelvic radiation

  • Post-void residual urine >100 mL at screening

  • Pelvic Organ Prolapse Quantification (POP-Q) stage >2

  • Positive urine culture at screening or dip stick for >1+ leukocyte esterase on the day of the procedures

  • Positive pregnancy test

  • Evidence of infection with hepatitis or human immunodeficiency virus (HIV)

  • Dementia

  • Clinically significant changes on the electrocardiogram (ECG) in women >50 years of age or in the clinical laboratory values as determined by the investigator

  • History of urge symptoms, diagnosis of interstitial cystitis, irritable bowel disease (requiring medications)

  • History of neurological deficit or injury that could affect laryngeal cough reflex, for example, central nervous system related conditions such as stroke or multiple sclerosis, head and neck cancer, major laryngeal surgery

  • History of neurological disorders leading to bladder abnormalities including stroke, Parkinsonism, multiple sclerosis, spinal cord surgery or spinal cord injury

  • Active hemorrhoids or history of recent (within 1 year) rectal surgery

  • Previous major pelvic or abdominal surgery (within 6 months)

  • Tobacco smokers and non-smokers who have >15 pack-year history or frequent (>2 times per week) marijuana smoking

  • Active sexually transmitted disease or genital herpes outbreak or symptomatic pelvic inflammatory disease

  • Pessary in place

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinical Physiology Associates, Inc Cape Coral Florida United States 33990
2 MIMA Century Research Associates Melbourne Florida United States 32901
3 Winter Park Urology Associates Orlando Florida United States 32803
4 Regional Urology, LLC Shreveport Louisiana United States 71106
5 Accumed Research Associates Garden City New York United States 11530
6 University Urology Associates Manhattan New York United States 10016
7 Carolina Urologic Research Center Myrtle Beach South Carolina United States 29572
8 Urology Associates of South Texas McAllen Texas United States 78503
9 Urology San Antonio Research San Antonio Texas United States 78229
10 Advanced Clinical Research West Jordan Utah United States 84088

Sponsors and Collaborators

  • Pneumoflex Systems, LLC
  • Ockham Development Group

Investigators

  • Study Director: Robert Addington, D.O., Pneumoflex Systems, LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Pneumoflex Systems, LLC
ClinicalTrials.gov Identifier:
NCT00801203
Other Study ID Numbers:
  • PNEU-01-004
First Posted:
Dec 3, 2008
Last Update Posted:
May 9, 2012
Last Verified:
May 1, 2012
Keywords provided by Pneumoflex Systems, LLC
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 9, 2012